ASH 2023 | Results from a Phase I trial of tinostamustine in patients with R/R classical HL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, shares insights into a Phase I trial evaluating the safety and efficacy of tinostamustine in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL; NCT02576496). Tinostamustine was well tolerated, with thrombocytopenia representing the most significant adverse event (AE), and may provide patients with heavily pre-treated disease with a novel therapeutic option. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
